ReviewVaccines2020
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- An mRNA Vaccine with Tandem Mutated HA-NA Confers Protection Against Multiple Strains of H1N1 Influenza.Vaccines · 2026Article
- Non-propagating RNA virus-vectored HA/NA vaccine prevents shedding of antigen-drifted H1N1 influenza virus in pigs.NPJ vaccines · 2026Article
- Immunity to hemagglutinin and neuraminidase results in additive reductions in airborne transmission of influenza H1N1 virus in ferrets.Science advances · 2026Article
- Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus.Nature communications · 2025Article
- Evolutionary trajectories and zoonotic potential of a PB2 mutation triad (I147T, K339T, and A588T) in avian influenza viruses.Veterinary research · 2025Article
- Production of Recombinant Neuraminidase NA Protein of Influenza A/H5N2 Virus and Its Application for the Detection of Virus-Specific IgG to Influenza A Viruses.Bulletin of experimental biology and medicine · 2025Article
- Review
- Development of an H9N2 vaccine strain with enhanced neuraminidase immunogenicity via dual hemagglutinin and neuraminidase modification.Journal of veterinary science · 2025Article
- Article
- Review
- Anti-Infective Screening of Selected Nine Cannabinoids AgainstCurrent issues in molecular biology · 2025Article
- Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study.BMC infectious diseases · 2025Article
- Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.Vaccines · 2024Article
- Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA.Nature communications · 2024Article
- Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.Journal of virology · 2024Article
- CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice.NPJ vaccines · 2024Article
- Development of a Fully Protective Pandemic Avian Influenza Subunit Vaccine in Insect Pupae.Viruses · 2024Article
- Glucose Catabolite Repression Participates in the Regulation of Sialidase Biosynthesis by Antarctic StrainJournal of fungi (Basel, Switzerland) · 2024Article
- Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase.Immunity · 2024Article
- Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.Influenza and other respiratory viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Neuraminidase (NA) is an influenza surface protein that helps to free viruses from mucin-associated decoy receptors and to facilitate budding from infected cells. Experiments have demonstrated that anti-NA antibodies protect animals against lethal influenza challenge by numerous strains, while decreasing pulmonary viral titers, symptoms, and lung lesions. Studies in humans during the influenza A/H3N2 pandemic and in healthy volunteers challenged with influenza A/H1N1 showed that anti-NA immunity reduced symptoms, nasopharyngeal viral shedding, and infection rates. Despite the benefits of anti-NA immunity, current vaccines focus on immunity against hemagglutinin and are not standardized to NA content leading to limited and variable NA immunogenicity. Purified NA has been shown to be safe and immunogenic in humans. Supplementing current vaccines with NA may be a simple strategy to improve suboptimal effectiveness. Immunity against NA is likely to be an important component of future universal influenza vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.